Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 4/20 | 0.50 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.49 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.49 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698953 | 0.94 | ACHE (0.57) | KMT2AMEN1ACHEDNMT1DNMT3L | |
| SCHEMBL22181870 | 0.84 | SIRT1 (0.57) | KMT2AMEN1POLB | |
| SCHEMBL9220706 | 0.82 | KMT2A (0.50) | KMT2AMEN1POLBCASP1RPS6KA2 | |
| SCHEMBL3455773 | 0.82 | RPS6KA2 (0.65) | CES1KMT2AMEN1RPS6KA2ACHE | |
| SCHEMBL1296639 | 0.81 | ACHE (0.64) | KMT2ATDP1MEN1ACHEDNMT1 | |
| SCHEMBL22181915 | 0.80 | ALDH1A1 (0.57) | KMT2AMEN1POLB | |
| SCHEMBL5683558 | 0.78 | ACHE (0.56) | ACHE | |
| SCHEMBL16087635 | 0.77 | RPS6KA2 (0.56) | KMT2AMEN1RPS6KA2ACHE | |
| SCHEMBL9218494 | 0.77 | ACHE (0.66) | ACHE | |
| SCHEMBL5422820 | 0.76 | TDP1 (0.66) | KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005075426-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS; PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2005-08-18 | — | — | WO | claimed |
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| EP-1551848-A1 | ARYLAMINE SUBSTUTUTED BICYCLIC HETEROAROMATIC COMPOUNDS AS P38 KINASE INHIBITORS | Celltech R & D Limited (GB) | 2005-07-13 | — | — | EP | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004000846-A1 | ARYLAMINE SUBSTUTUTED BICYCLIC HETEROAROMATIC COMPOUNDS AS P38 KINASE INHIBITORS | CELLTECH R & D LIMITED (GB) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | CES1 450/4885KMT2A 1919/4885TDP1 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.